Primecap Management CO Zentalis Pharmaceuticals, Inc. Transaction History

Primecap Management CO

$127 Billion
Q4 2024

A detailed history of Primecap Management CO transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Primecap Management CO holds 1,520,630 shares of ZNTL stock, worth $3.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,520,630

Previous 1,498,030 1.51%

Holding current value

$3.13 Million

Previous $5.5 Million 16.19%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	BUY	$2.7 - $4.03 $61,020 - $91,078	22,600 Added 1.51%	1,520,630 $4.61 Million
Q3 2024 Nov 08, 2024	BUY	$2.9 - $4.57 $770,501 - $1.21 Million	265,690 Added 21.56%	1,498,030 $5.5 Million
Q2 2024 Aug 09, 2024	BUY	$4.09 - $16.13 $277,015 - $1.09 Million	67,730 Added 5.82%	1,232,340 $5.04 Million
Q1 2024 May 13, 2024	BUY	$10.83 - $16.49 $1.53 Million - $2.33 Million	141,260 Added 13.8%	1,164,610 $18.4 Million
Q4 2023 Feb 09, 2024	SELL	$9.84 - $20.13 $102,336 - $209,352	-10,400 Reduced 1.01%	1,023,350 $15.5 Million
Q3 2023 Nov 13, 2023	SELL	$19.63 - $28.29 $1.52 Million - $2.19 Million	-77,400 Reduced 6.97%	1,033,750 $20.7 Million
Q2 2023 Aug 11, 2023	SELL	$17.41 - $30.05 $309,375 - $533,988	-17,770 Reduced 1.57%	1,111,150 $31.3 Million
Q1 2023 May 15, 2023	SELL	$16.14 - $24.94 $20,175 - $31,175	-1,250 Reduced 0.11%	1,128,920 $19.4 Million
Q4 2022 Feb 13, 2023	SELL	$18.07 - $25.6 $895,007 - $1.27 Million	-49,530 Reduced 4.2%	1,130,170 $22.8 Million
Q3 2022 Nov 14, 2022	SELL	$20.23 - $31.73 $248,829 - $390,279	-12,300 Reduced 1.03%	1,179,700 $25.6 Million
Q2 2022 Aug 11, 2022	SELL	$17.91 - $52.25 $297,126 - $866,827	-16,590 Reduced 1.37%	1,192,000 $33.5 Million
Q1 2022 May 11, 2022	SELL	$41.58 - $80.89 $1.87 Million - $3.64 Million	-45,050 Reduced 3.59%	1,208,590 $55.8 Million
Q4 2021 Feb 11, 2022	SELL	$66.92 - $84.79 $5.49 Million - $6.95 Million	-81,980 Reduced 6.14%	1,253,640 $105 Million
Q3 2021 Nov 12, 2021	SELL	$46.83 - $73.5 $608,321 - $954,765	-12,990 Reduced 0.96%	1,335,620 $89 Million
Q2 2021 Aug 10, 2021	BUY	$37.41 - $62.25 $493,063 - $820,455	13,180 Added 0.99%	1,348,610 $71.7 Million
Q1 2021 May 14, 2021	SELL	$35.69 - $52.72 $1.29 Million - $1.91 Million	-36,260 Reduced 2.64%	1,335,430 $57.9 Million
Q4 2020 Feb 08, 2021	SELL	$31.71 - $57.97 $350,712 - $641,148	-11,060 Reduced 0.8%	1,371,690 $71.2 Million
Q3 2020 Nov 13, 2020	BUY	$27.03 - $47.97 $19.5 Million - $34.7 Million	722,800 Added 109.52%	1,382,750 $45.2 Million
Q2 2020 Aug 13, 2020	BUY	$23.2 - $54.8 $15.3 Million - $36.2 Million	659,950 New	659,950 $31.7 Million

Others Institutions Holding ZNTL

# of Institutions

136

Shares Held

67.8M

Call Options Held

48.5K

Put Options Held

89.6K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $117M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Primecap Management CO with notifications on news.

Account

Primecap Management CO Zentalis Pharmaceuticals, Inc. Transaction History